Xilio Therapeutics to Present at Upcoming Investor Conferences

2023-02-27

免疫疗法

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences: Cowen 43rd Annual Healthcare Conference on Monday, March 6, 2023, at 9:10 a.m. ET as part of a discussion called Novel Immuno-Oncology (IO) Corporate Panel. Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, with a virtual presentation at 4:00 p.m. ET. A live webcast of the presentations can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at . A replay of the webcasts will be archived on the website for 30 days following each presentation. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.). This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release. For Investor Inquiries: Melissa Forst Argot Partners xilio@argotpartners.com For Media Inquiries:  Julissa Viana Vice President, Corporate Communications media@xiliotx.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构